INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION
The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | CAO, Jingrong WANG, Tiansheng LEDFORD, Brian SENTER, Timothy J MEDEK, Ales DENIS, Francois FORTIER, Anne NICOLAS, Olivier DORSCH, Warren A HU, Kan-Nian COME, Jon H SAYEGH, Camil GAGNON, Kevin WITKOS, Faith KRUEGER, Elaine B HAMEL, Martine NANTHAKUMAR, Suganthini S DAKIN, Leslie A SHI, Yi BRODNEY, Michael SHRESTHA, Muna ROSE, Peter |
| description | The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD). |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MA54538A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MA54538A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MA54538A3</originalsourceid><addsrcrecordid>eNrjZDD19PPwdPIMcQ0NClZwUXcM8PcxVHANUfABCwQE-Tsf7nQ53AmSCw3x9PEMdgzx9PfjYWBNS8wpTuWF0twMsm6uIc4euqkF-fGpxQWJyal5qSXxvo6mJqbGFo7GhOQBSfUndQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION</title><source>esp@cenet</source><creator>CAO, Jingrong ; WANG, Tiansheng ; LEDFORD, Brian ; SENTER, Timothy J ; MEDEK, Ales ; DENIS, Francois ; FORTIER, Anne ; NICOLAS, Olivier ; DORSCH, Warren A ; HU, Kan-Nian ; COME, Jon H ; SAYEGH, Camil ; GAGNON, Kevin ; WITKOS, Faith ; KRUEGER, Elaine B ; HAMEL, Martine ; NANTHAKUMAR, Suganthini S ; DAKIN, Leslie A ; SHI, Yi ; BRODNEY, Michael ; SHRESTHA, Muna ; ROSE, Peter</creator><creatorcontrib>CAO, Jingrong ; WANG, Tiansheng ; LEDFORD, Brian ; SENTER, Timothy J ; MEDEK, Ales ; DENIS, Francois ; FORTIER, Anne ; NICOLAS, Olivier ; DORSCH, Warren A ; HU, Kan-Nian ; COME, Jon H ; SAYEGH, Camil ; GAGNON, Kevin ; WITKOS, Faith ; KRUEGER, Elaine B ; HAMEL, Martine ; NANTHAKUMAR, Suganthini S ; DAKIN, Leslie A ; SHI, Yi ; BRODNEY, Michael ; SHRESTHA, Muna ; ROSE, Peter</creatorcontrib><description>The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).</description><language>fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211027&DB=EPODOC&CC=MA&NR=54538A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211027&DB=EPODOC&CC=MA&NR=54538A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CAO, Jingrong</creatorcontrib><creatorcontrib>WANG, Tiansheng</creatorcontrib><creatorcontrib>LEDFORD, Brian</creatorcontrib><creatorcontrib>SENTER, Timothy J</creatorcontrib><creatorcontrib>MEDEK, Ales</creatorcontrib><creatorcontrib>DENIS, Francois</creatorcontrib><creatorcontrib>FORTIER, Anne</creatorcontrib><creatorcontrib>NICOLAS, Olivier</creatorcontrib><creatorcontrib>DORSCH, Warren A</creatorcontrib><creatorcontrib>HU, Kan-Nian</creatorcontrib><creatorcontrib>COME, Jon H</creatorcontrib><creatorcontrib>SAYEGH, Camil</creatorcontrib><creatorcontrib>GAGNON, Kevin</creatorcontrib><creatorcontrib>WITKOS, Faith</creatorcontrib><creatorcontrib>KRUEGER, Elaine B</creatorcontrib><creatorcontrib>HAMEL, Martine</creatorcontrib><creatorcontrib>NANTHAKUMAR, Suganthini S</creatorcontrib><creatorcontrib>DAKIN, Leslie A</creatorcontrib><creatorcontrib>SHI, Yi</creatorcontrib><creatorcontrib>BRODNEY, Michael</creatorcontrib><creatorcontrib>SHRESTHA, Muna</creatorcontrib><creatorcontrib>ROSE, Peter</creatorcontrib><title>INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION</title><description>The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDD19PPwdPIMcQ0NClZwUXcM8PcxVHANUfABCwQE-Tsf7nQ53AmSCw3x9PEMdgzx9PfjYWBNS8wpTuWF0twMsm6uIc4euqkF-fGpxQWJyal5qSXxvo6mJqbGFo7GhOQBSfUndQ</recordid><startdate>20211027</startdate><enddate>20211027</enddate><creator>CAO, Jingrong</creator><creator>WANG, Tiansheng</creator><creator>LEDFORD, Brian</creator><creator>SENTER, Timothy J</creator><creator>MEDEK, Ales</creator><creator>DENIS, Francois</creator><creator>FORTIER, Anne</creator><creator>NICOLAS, Olivier</creator><creator>DORSCH, Warren A</creator><creator>HU, Kan-Nian</creator><creator>COME, Jon H</creator><creator>SAYEGH, Camil</creator><creator>GAGNON, Kevin</creator><creator>WITKOS, Faith</creator><creator>KRUEGER, Elaine B</creator><creator>HAMEL, Martine</creator><creator>NANTHAKUMAR, Suganthini S</creator><creator>DAKIN, Leslie A</creator><creator>SHI, Yi</creator><creator>BRODNEY, Michael</creator><creator>SHRESTHA, Muna</creator><creator>ROSE, Peter</creator><scope>EVB</scope></search><sort><creationdate>20211027</creationdate><title>INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION</title><author>CAO, Jingrong ; WANG, Tiansheng ; LEDFORD, Brian ; SENTER, Timothy J ; MEDEK, Ales ; DENIS, Francois ; FORTIER, Anne ; NICOLAS, Olivier ; DORSCH, Warren A ; HU, Kan-Nian ; COME, Jon H ; SAYEGH, Camil ; GAGNON, Kevin ; WITKOS, Faith ; KRUEGER, Elaine B ; HAMEL, Martine ; NANTHAKUMAR, Suganthini S ; DAKIN, Leslie A ; SHI, Yi ; BRODNEY, Michael ; SHRESTHA, Muna ; ROSE, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MA54538A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CAO, Jingrong</creatorcontrib><creatorcontrib>WANG, Tiansheng</creatorcontrib><creatorcontrib>LEDFORD, Brian</creatorcontrib><creatorcontrib>SENTER, Timothy J</creatorcontrib><creatorcontrib>MEDEK, Ales</creatorcontrib><creatorcontrib>DENIS, Francois</creatorcontrib><creatorcontrib>FORTIER, Anne</creatorcontrib><creatorcontrib>NICOLAS, Olivier</creatorcontrib><creatorcontrib>DORSCH, Warren A</creatorcontrib><creatorcontrib>HU, Kan-Nian</creatorcontrib><creatorcontrib>COME, Jon H</creatorcontrib><creatorcontrib>SAYEGH, Camil</creatorcontrib><creatorcontrib>GAGNON, Kevin</creatorcontrib><creatorcontrib>WITKOS, Faith</creatorcontrib><creatorcontrib>KRUEGER, Elaine B</creatorcontrib><creatorcontrib>HAMEL, Martine</creatorcontrib><creatorcontrib>NANTHAKUMAR, Suganthini S</creatorcontrib><creatorcontrib>DAKIN, Leslie A</creatorcontrib><creatorcontrib>SHI, Yi</creatorcontrib><creatorcontrib>BRODNEY, Michael</creatorcontrib><creatorcontrib>SHRESTHA, Muna</creatorcontrib><creatorcontrib>ROSE, Peter</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CAO, Jingrong</au><au>WANG, Tiansheng</au><au>LEDFORD, Brian</au><au>SENTER, Timothy J</au><au>MEDEK, Ales</au><au>DENIS, Francois</au><au>FORTIER, Anne</au><au>NICOLAS, Olivier</au><au>DORSCH, Warren A</au><au>HU, Kan-Nian</au><au>COME, Jon H</au><au>SAYEGH, Camil</au><au>GAGNON, Kevin</au><au>WITKOS, Faith</au><au>KRUEGER, Elaine B</au><au>HAMEL, Martine</au><au>NANTHAKUMAR, Suganthini S</au><au>DAKIN, Leslie A</au><au>SHI, Yi</au><au>BRODNEY, Michael</au><au>SHRESTHA, Muna</au><au>ROSE, Peter</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION</title><date>2021-10-27</date><risdate>2021</risdate><abstract>The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | fre |
| recordid | cdi_epo_espacenet_MA54538A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T14%3A16%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CAO,%20Jingrong&rft.date=2021-10-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMA54538A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |